scholarly journals Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer—Incidence, radiological features and clinical characteristics

Lung Cancer ◽  
2017 ◽  
Vol 106 ◽  
pp. 33-36 ◽  
Author(s):  
Darragh F. Halpenny ◽  
Sinead McEvoy ◽  
Angela Li ◽  
Sumar Hayan ◽  
Marinela Capanu ◽  
...  
Radiology ◽  
1999 ◽  
Vol 211 (1) ◽  
pp. 137-145 ◽  
Author(s):  
Franklin Earnest ◽  
Jay H. Ryu ◽  
Gary M. Miller ◽  
Patrick H. Luetmer ◽  
Lee A. Forstrom ◽  
...  

2009 ◽  
Vol 27 (18_suppl) ◽  
pp. CRA1500-CRA1500 ◽  
Author(s):  
R. T. Chlebowski ◽  
A. Schwartz ◽  
H. Wakelee ◽  
G. L. Anderson ◽  
M. L. Stefanick ◽  
...  

CRA1500 Background: Sex differences in lung cancer outcome suggest a potential hormonal influence; however, observational studies provide mixed findings regarding menopausal hormone therapy (HT) and lung cancer. Methods: Secondary analyses of the WHI randomized, placebo-controlled trial of daily conjugated equine estrogen (CEE, 0.625 mg) plus medroxyprogesterone acetate (MPA, 2.5 mg) in 16,608 multi-ethnic postmenopausal women, aged 50–79 were conducted on lung cancer incidence and mortality. Lung cancers were confirmed by medical record review. Results: Groups were balanced for age, race/ethnicity, and prior HT. Smoking status was also comparable (never 50%, past 40%, current 10% in both groups). Cumulative risk for lung cancer was highest in current (0.51%), compared to past (0.14%) and never (0.04%) smokers. After 5.6 years on trial intervention and 2.4 years additional follow-up (median), small cell lung cancer incidence was comparable between randomization groups (total n=26), as was subsequent small cell lung cancer mortality. Although a trend for more non-small cell lung cancer (NSCLC) diagnoses in the active hormone group was not significant (p=0.12), an apparent divergence emerged after five years, with more diagnoses in the CEE+MPA group. In addition, mortality after NSCLC diagnosis was significantly higher for the CEE+MPA group (46.3% vs 27.0%, respectively, hazard ratio (HR) 1.59, 95% CI 1.03–2.46, p=0.04). As a result, CEE+MPA group women were more likely to die from NSCLC than those on placebo (p=0.02). Conclusions: Use of CEE + MPA for over 5 years increases a woman's risk for NSCLC mortality, the leading cause of cancer death in women. These data, together with recent results indicating higher breast cancer risk (Cancer Res 2009;69(2):78s), suggest cancer impact should influence risk-to-benefit consideration for combined HT use. [Table: see text] [Table: see text]


2019 ◽  
Vol 16 (6) ◽  
pp. 531-541
Author(s):  
HELENA LINARDOU ◽  
VASSILIKI KOTOULA ◽  
GEORGE KOUVATSEAS ◽  
GIANNIS MOUNTZIOS ◽  
VASILIOS KARAVASILIS ◽  
...  

Haigan ◽  
1987 ◽  
Vol 27 (1) ◽  
pp. 1-10
Author(s):  
Sogo Iioka ◽  
Kazuo Saotome ◽  
Yoshiyasu Sanbe ◽  
Toshimasa Tsuchiya ◽  
Masanobu Hirata ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document